Compare LEXX & JTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LEXX | JTAI |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 8.1M |
| IPO Year | 2011 | 2021 |
| Metric | LEXX | JTAI |
|---|---|---|
| Price | $4.53 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.2K | ★ 61.2K |
| Earning Date | 11-27-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.69 |
| EPS | ★ N/A | N/A |
| Revenue | $705,923.00 | ★ $9,177,767.00 |
| Revenue This Year | N/A | $0.26 |
| Revenue Next Year | $6,915.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 52.05 | N/A |
| 52 Week Low | $0.35 | $0.80 |
| 52 Week High | $21.60 | $2,082.00 |
| Indicator | LEXX | JTAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 36.87 |
| Support Level | $2.67 | $0.80 |
| Resistance Level | $10.26 | $1.09 |
| Average True Range (ATR) | 0.41 | 0.10 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 74.74 | 27.59 |
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Jet AI Inc is principally involved in the sale of fractional and whole interests in aircraft, the sale of jet cards, which enable holders to use certain of the company's and other's aircraft at agreed-upon rates, the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third-party carriers as well as via the company's leased and managed aircraft, direct chartering of its HondaJet Elite aircraft by Cirrus Aviation Services, aircraft brokerage and monthly management and hourly operation of customer aircraft. It also offers the SaaS software to aircraft owners and operators generally: Reroute AI; and DynoFlight. The company operates in a single operating and reportable segment which is private aviation services.